This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Jazz Pharma Completes NDA Filing for Leukemia Drug to FDA
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced that it has completed the rolling submission of a new drug application (NDA) to the FDA, seeking approval for its leukemia candidate, Vyxeos.
Jazz Pharma (JAZZ) Up 7.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Jazz Pharma (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz Sleep Disorder Drug Positive in Phase III Studies
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced positive efficacy results from two phase III studies evaluating the safety and efficacy of its lead pipeline candidate JZP-110 for the treatment of excessive sleepiness.
Jazz Initiates Phase III Study for Narcolepsy Candidate
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced the initiation of patient enrollment in a phase III study evaluating the efficacy and safety of its pipeline candidate, JZP-258, for the potential treatment of adult narcolepsy patients.
Jazz Pharma (JAZZ) Q4 Earnings Beat, Sales Miss Estimates
by Zacks Equity Research
Jazz Pharmaceuticals Public Limited Company (JAZZ) reported fourth-quarter 2016 earnings of $1.91 per share which beat the Zacks Consensus Estimate of $1.65.
Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) is scheduled to report fourth-quarter 2016 results on Feb 28 after the market closes.
5 Drug Stocks Poised to Beat Earnings Estimates in Q4
by Arpita Dutt
Medical is one of the few sectors that has consistently recorded earnings growth over the last 4 quarters. Here is a look at 5 pharma and biotech stocks that look set to beat Q4 earnings estimates.
Can Jazz Pharmaceuticals Be a Top Choice for Value Investors?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Can Jazz Pharmaceuticals Be a Top Choice for Value Investors?
by Zacks Equity Research
Let's see if Jazz Pharmaceuticals Public Limited Company (JAZZ) stock is a good choice for value-oriented investors right now from multiple angles.
Jazz Begins Phase III Study for Label Expansion of Defitelio
by Zacks Equity Research
Jazz Pharmaceuticals Public Limited Company (JAZZ) announced the initiation of a phase III clinical study on its marketed drug, Defitelio (defibrotide), for the potential prevention of veno-occlusive disease.
Bear of the Day: Jazz Pharma (JAZZ)
by David Bartosiak
A little less JAZZ and a lot more blues has been playing lately